Sign up Australia
Proactive Investors - Run By Investors For Investors

Viralytics Ltd reports positive results of melanoma cancer fighting combination

Viralytics Ltd reports positive results of melanoma cancer fighting combination

Viralytics Ltd (ASX:VLA) has reported positive results from a Phase 1b clinical trial of late-stage melanoma cancer patients in multiple U.S. sites evaluating the safety and anti-cancer activity endpoints of CAVATAK coupled with a cancer drug YERVOY.

There were 11 advanced melanoma patients enrolled to date.

The preliminary finding from the investigator is that out of five patients not previously treated with YERVOY, four had clinically meaningful tumor regressions in sites injected with CAVATAK in patients with advanced melanoma.

The initial findings confirm that systemic immunity against melanoma can be achieved with this combination. The  study is ongoing with updates in coming months.

There were no dose limiting toxicities, and no CAVATAK-related grade 3 or higher adverse events.

The results add to the clinical and preclinical evidence pointing to CAVATAK’s potential to enhance the activity of checkpoint inhibitors across a range of cancer indications.

CAVATAK and YERVOY are a new class of cancer treatments known as immunotherapies, designed to enhance the body’s own defences in fighting cancer.

CAVATAK is currently being studied in Phase 1 and 2 clinical trials for the treatment of melanoma, as well as prostate, bladder and lung cancers.

In December 2015, Viralytics completed a share placement that raised $28.4 million at $0.615 per share.

Additionally, Viralytics raised $4 million via a share purchase plan to retail investors in January 2016, following applications well in excess of $10 million.

 

Proactive Investors is a global leader reporting financial news, media, research and hosts events for listed emerging growth companies and investors across four continents.

View full VLA profile View Profile

Viralytics Timeline

Newswire
December 10 2015

Related Articles

mri scanner
July 24 2017
The Assessa PML platform is designed to facilitate the remote transfer, management and storage of MRI scans to help doctors detect progressive multifocal leukoencephalopathy
1506367758_shutterstock_118491940.jpg
September 27 2017
The firm received an order for its clinical research use only (RUO) kits from a large, multinational pharma company
e-Therapeutics
August 17 2017
E-Therapeutics’ network-driven drug discovery platform looks at the broader interactions within disease mechanisms

No investment advice

The information on this Site is of a general nature only. It does not take your specific needs or circumstances into consideration, so you should look at your own financial position, objectives and requirements and seek financial advice before making any financial decisions. You acknowledge and understand that neither the Company, its related bodies corporate, the information providers or their affiliates will advise you personally about the nature, potential value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter. You should read our FSG and any other relevant disclosure documents and if necessary seek persona advice prior to making any investment decision.

You understand and agree that no Content (as defined below) published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person.

You understand that in certain circumstances the Company, its related bodies corporate, the information providers or their affiliates may have received, or be entitled to receive, financial or other consideration in connection with promoting, and providing information about, certain entities on the Site and in communications otherwise provided to you.

You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate. From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Before you act on any general advice we provide, please consider whether it is appropriate for your personal circumstances.

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use